This document discusses the use of GEANT4 and the GATE toolkit for simulating emission tomography systems like PET and SPECT. It provides an overview of why Monte Carlo simulations are useful for imaging, the architecture of GATE which is based on GEANT4, and how GATE handles geometry, time, physics processes, digitization and more. It also provides examples of how GATE has been validated against real patient and preclinical imaging systems and discusses its potential applications and current limitations like long simulation times.
This document outlines the governance policies and procedures for the TexasOnline 2.0 program. It defines key terms and describes the governance approach, roles and responsibilities of parties involved, governance committees and teams, policies, and procedures. Procedures include the business case process, architectural review process, change management process, and financial management.
The document discusses the mission and function of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC). The subcommittee evaluates and prioritizes new cancer therapeutics for children and provides recommendations to ensure timely access. It also advises on improving consistency in availability. Membership includes experts from relevant fields. The Office of Oncology Drug Products at the FDA's Center for Drug Evaluation and Research oversees oncology product review and policy. It coordinates activities within the FDA and with external groups. The document also outlines the roles of the Radioactive Drug Research Committee and the FDA's divisions of oncology products.
